Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
1. |
ECCT/25/03/07 | Sparkle - Site 1405 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Prof Videlis Nduba Site(s) in Kenya 1. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 2. Ahero Clinical trials Unit (Kisumu county) 3. International Cancer institute (Uasin Gishu county) 4. Kondele Childrens Hospital (Kisumu county) 5. Gertrudes Children’s Hospital (Nairobi City county) 6. Victoria Biomedical Research Institute (Kisumu county) |
View |
2. |
ECCT/25/03/04 | Ndovu RCT Investigating the optimal management of dolutegravir resistance: an open-label randomised controlled trial of maintaining dolutegravir or switch to ritonavir-boosted darunavir |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Kenyatta National Hospital (KNH) (Nairobi City county) 2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 3. Bomu Hospital (Mombasa county) |
View |
3. |
ECCT/25/02/09 | DASH II Study Diagnostic Access to Self-Care & Health Services in Low- and Middle-Income Countries (DASH) – Phase II Study |
Principal Investigator(s) 1. ELIZABETH ANNE BUKUSI Site(s) in Kenya Migori County |
View |
4. |
ECCT/25/02/08 | Clearance of High-Risk HPV A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts |
Principal Investigator(s) 1. Valentine Chepkorir Sing’oei Site(s) in Kenya 1. KEMRI –USAMRD-A, Kombewa Clinical Research Centre (Kisumu county) |
View |
5. |
ECCT/25/02/06 | Clearance of High-Risk HPV A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts |
Principal Investigator(s) 1. Omu Anzala Site(s) in Kenya 1. KAVI-Institute of Clinical Research (KAVI - ICR) (Nairobi City county) |
View |